EIKN (NASDAQ:EIKN) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Consensus "Moderate Buy": Seven analysts cover EIKN with a consensus rating of Moderate Buy (five buys, one hold, one sell) and an average 12‑month target of $25.60.
• Major firms have recently initiated bullish coverage—Bank of America (buy, $34 target), JPMorgan (overweight, $29) and Mizuho (outperform, $26)—while Zacks rates it a hold.
• Shares opened at $11.55, below the 50‑day SMA of $12.17 and well under analyst targets; EIKN is a late‑stage clinical biopharma focused on oncology led by experienced drug developers.

EIKN (NASDAQ:EIKN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $25.60.

EIKN has been the subject of several research analyst reports. Bank of America initiated coverage on EIKN in a research note on Monday, March 2nd. They set a "buy" rating and a $34.00 target price for the company. Cantor Fitzgerald initiated coverage on EIKN in a research note on Monday, March 2nd. They set an "overweight" rating for the company. Zacks Research raised EIKN to a "hold" rating in a research note on Friday, February 27th. JPMorgan Chase & Co. initiated coverage on EIKN in a research note on Monday, March 2nd. They set an "overweight" rating and a $29.00 target price for the company. Finally, Mizuho assumed coverage on EIKN in a research note on Monday, March 2nd. They set an "outperform" rating and a $26.00 target price for the company.

EIKN Price Performance

Shares of EIKN stock opened at $11.55 on Tuesday. The stock's 50 day simple moving average is $12.17. EIKN has a 1-year low of $8.58 and a 1-year high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.